Keyphrases
Cost-effectiveness
100%
Antepartum
100%
Intravenous Immunoglobulin (IVIg)
100%
Neonatal Alloimmune Thrombocytopenia
100%
Empirical Therapy
50%
Fetal Blood Sampling
50%
Quality-adjusted Life Years
25%
Fetus
12%
Health Outcomes
12%
Pharmacotherapy
12%
Platelets
12%
At-risk
12%
Sensitivity Analysis
12%
High-risk Women
12%
Perinatal Death
12%
Cost-effective Strategy
12%
Treatment of Women
12%
Platelet Levels
12%
Neurologic Deficit
12%
Week of Gestation
12%
Decision-analytic Model
12%
Intravenous Immunoglobulin Therapy
12%
Marginal Cost
12%
Life-years Gained
12%
Immune Thrombocytopenia
12%
Intravenous Corticosteroids
12%
Cost-effectiveness Ratio
12%
Intrapartum Care
12%
QALYs Gained
12%
Fetuses-at-risk
12%
Medicine and Dentistry
Immunoglobulin
100%
Cost-Effectiveness Analysis
100%
Neonatal Alloimmune Thrombocytopenia
100%
Blood Sampling
80%
Quality Adjusted Life Year
60%
Health Care Cost
60%
Platelet
40%
Drug Therapy
20%
Health Outcomes
20%
Thrombocytopenia
20%
Intravenous Immunoglobulin Therapy
20%
Perinatal Death
20%
Fetus Risk
20%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Immunoglobulin
100%
Neonatal Alloimmune Thrombocytopenia
100%
Blood Sampling
80%
Quality Adjusted Life Year
60%
Immunotherapy
20%
Antepartum Care
20%
Health Outcomes
20%
Drug Therapy
20%
Perinatal Death
20%
Fetus Risk
20%
Thrombocytopenia
20%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin
100%
Neonatal Alloimmune Thrombocytopenia
100%
Pharmacotherapy
20%
Perinatal Death
20%
Fetus Risk
20%
Immunotherapy
20%
Thrombocytopenia
20%